• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

    5/13/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care
    Get the next $INO alert in real time by email
    • On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025
      • Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25
    • Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025
      • INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery
    • Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production
      • Preprint manuscript available on ResearchSquare.com 

    PLYMOUTH MEETING, Pa., May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.

    (PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

    "I'm pleased to confirm that we remain on track to submit our BLA for INO-3107 this year. As previously stated, our goal is to begin rolling submission in mid-2025, complete the submission in the second half of 2025 and receive file acceptance from the FDA by year end. If we receive priority review, it could allow for a PDUFA date in mid-2026," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We continue to focus our efforts and resources toward bringing this important product candidate to patients eager for a non-surgical therapeutic option to treat this devastating disease. Based on market research, we believe INO-3107 could be the preferred product for patients and providers, if approved. Beyond INO-3107, we are excited about the recently announced promising data from a proof-of-concept Phase 1 clinical trial with our next-generation DMAb technology, as well as the potential of our entire DNA medicines pipeline."

    Operational Highlights

    INO-3107 – Recurrent Respiratory Papillomatosis (RRP)

    The DV testing for INO-3107 has been initiated and is anticipated to be completed in the first half of 2025. INOVIO plans to begin rolling submission of the BLA in mid-2025 under FDA's accelerated approval program, subject to FDA concurrence, with the goal of completing the submission in the second half of 2025 and receiving FDA acceptance of the submission by the end of the year. FDA has previously awarded breakthrough therapy designation for INO-3107 and INOVIO plans to request priority review of its BLA, which if granted would allow for an FDA approval decision (PDUFA date) in mid-2026.

    INOVIO is conducting ongoing market research with physicians, patients and payors to support its commercial readiness plans. Additionally, clinical and immunology data from a Phase 1/2 trial was published in the peer-reviewed scientific journal Nature Communications in February 2025 and longer-term follow up data was submitted to another peer-reviewed journal for publication. INOVIO has presented key efficacy, safety, immunological and durability data from the Phase 1/2 trial at a number of scientific conferences, including the following:

    • National HPV Conference (April 15)
    • World Vaccine Congress (April 21)
    • Festival of Biologics (April 23)
    • European Laryngological Society (ELS) Annual Congress (May 9)
    • American Society of Gene and Cell Therapy (May 13)

    On May 14th INOVIO will also be presenting at the American Broncho-Esophagological Association Combined Otolaryngology Spring Meeting (ABEA/COSM), the largest US national meeting for otolaryngologists, the specialist physicians who treat the majority of RRP patients.

    Available abstracts are posted to INOVIO's website following presentations.

    DNA-Encoded Monoclonal Antibodies (DMAbs)

    In the first quarter, INOVIO and its collaborators announced top-line interim results from an ongoing Phase 1 proof-of-concept trial evaluating its DMAb technology. Additional data from this trial will be presented at the annual meeting of the American Society of Gene and Cell Therapy in May. The data is also anticipated to be published in a peer-reviewed journal. As previously announced, the interim results are currently available in preprint form on Research Square. In the trial, which used monoclonal antibodies against COVID-19 as proof-of-concept targets, 100% (24/24) of participants who reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies, a common challenge observed in other gene-based delivery platforms, such as adeno-associated virus-mediated antibody expression.

    First Quarter 2025 Financial Results

    • Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025, decreased to $16.1 million from $20.9 million for the same period in 2024. The decrease was primarily the result of lower drug manufacturing and immunology expenses related to INO-3107, lower contract labor expenses and lower expensed inventory, partially offset by higher engineering professional and outside services related to our device development, among other variances.



    • General and Administrative (G&A) Expenses: G&A expenses decreased to $9.0 million for the three months ended March 31, 2025 from $10.6 million for the same period in 2024. The decrease was primarily related to a decrease in legal expenses and employee and consultant stock-based compensation, among other variances.



    • Total Operating Expenses: Total operating expenses decreased to $25.1 million for the three months ended March 31, 2025 from $31.5 million for the same period in 2024.



    • Net Loss: Net loss for the three months ended March 31, 2025 decreased to $19.7 million, or $0.51 per basic and diluted share, from a net loss of $30.5 million, or $1.31 per basic and diluted share, for the three months ended March 31, 2024.



    • Shares Outstanding: As of March 31, 2025, INOVIO had 36.7 million common shares outstanding and 51.3 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding common stock warrants, including pre-funded warrants and stock options, restricted stock units and convertible preferred stock.



    • Cash, Cash Equivalents and Short-term Investments: As of March 31, 2025, cash, cash equivalents and short-term investments were $68.4 million, compared to $94.1 million as of December 31, 2024.

    INOVIO's balance sheet and statement of operations are provided below. Additional information is included in INOVIO's quarterly report on Form 10-Q for the quarter ended March 31, 2025, which can be accessed at: http://ir.inovio.com/financials/default.aspx.

    Cash Guidance

    INOVIO estimates its current cash, cash equivalents and short-term investments balances to support the company's operations into the first quarter of 2026. This projection includes an operational net cash burn estimate of approximately $22 million for the second quarter of 2025. These projections do not include any further capital-raising activities that INOVIO may undertake. 

    Conference Call / Webcast Information

    INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.

    About INOVIO's DNA Medicines Platform

    INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.

    About INOVIO

    INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

    Forward-Looking Statements

    This press release contains certain forward-looking statements relating to our business, including the planned initiation and conduct of pre-clinical studies and clinical trials and the availability and timing of data from those studies and trials, the completion of the FDA-required device verification testing, the planned submission of a BLA in mid-2025 and request for priority review and goal of FDA's acceptance of the submission by the end of 2025, the potential commercial launch of INO-3107 if regulatory approval is obtained, the potential benefits of our product candidates, expectations regarding sufficiency of our cash resources into the first quarter of 2026 and expected cash burn for the second quarter of 2025. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.

    Contacts

    Media: Jennie Willson, (267) 429-8567, [email protected]

    Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, [email protected] 

     

    Inovio Pharmaceuticals, Inc.

    CONSOLIDATED BALANCE SHEETS





    March 31,

     2025



    December 31,

     2024



    (Unaudited)





    ASSETS







    Current assets:







    Cash and cash equivalents

    $39,915,447



    $65,813,297

    Short-term investments

    28,447,097



    28,300,232

    Accounts receivable from affiliated entity

    1,310,237



    1,199,056

    Prepaid expenses and other current assets

    2,221,668



    2,517,465

    Total current assets

    71,894,449



    97,830,050

    Fixed assets, net

    3,347,824



    3,659,818

    Investments in affiliated entity

    2,308,975



    1,613,844

    Operating lease right-of-use assets

    7,741,757



    8,113,840

    Other assets

    1,979,654



    1,979,654

    Total assets

    $87,272,659



    $113,197,206

    LIABILITIES AND STOCKHOLDERS' EQUITY







    Current liabilities:







    Accounts payable and accrued expenses

    $12,919,788



    $16,200,013

    Accounts payable and accrued expenses due to affiliated entity     

    469,637



    1,351,163

    Accrued clinical trial expenses

    1,819,237



    2,021,860

    Common stock warrant liability

    9,542,316



    13,255,188

    Operating lease liability

    2,575,902



    2,497,360

    Total current liabilities

    27,326,880



    35,325,584

    Operating lease liability, net of current portion

    8,695,055



    9,367,827

    Total liabilities

    36,021,935



    44,693,411

    Stockholders' equity:







    Preferred stock

    —



    —

    Common stock

    36,674



    36,099

    Additional paid-in capital

    1,801,789,329



    1,799,362,625

    Accumulated deficit

    (1,749,913,959)



    (1,730,219,262)

    Accumulated other comprehensive loss

    (661,320)



    (675,667)

    Total Inovio Pharmaceuticals, Inc. stockholders' equity

    51,250,724



    68,503,795

    Total liabilities and stockholders' equity

    $87,272,659



    $113,197,206

     

    Inovio Pharmaceuticals, Inc.

    CONSOLIDATED STATEMENTS OF OPERATIONS 





    Three Months Ended March 31,



    2025



    2024

    Revenues:







    Revenue from collaborative arrangements

    $65,343



    $—

    Operating expenses:







    Research and development

    16,090,902



    20,913,790

    General and administrative

    9,024,970



    10,571,179

    Total operating expenses

    25,115,872



    31,484,969

    Loss from operations

    (25,050,529)



    (31,484,969)

    Other income (expense):







    Interest income

    808,077



    1,500,290

    Interest expense

    —



    (177,833)

    Change in fair value of common stock warrant liability

    3,712,872



    —

    Gain (loss) on investment in affiliated entity

    695,131



    (126,018)

    Net unrealized gain on available-for-sale equity securities

    140,234



    500,877

    Other expense, net

    (482)



    (682,218)

    Net loss

    $(19,694,697)



    $(30,469,871)

    Net loss per share







              Basic and diluted

    $(0.51)



    $(1.31)

    Weighted average number of common shares used to compute net loss per     

    share







              Basic and diluted

    38,613,653



    23,291,512

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-first-quarter-2025-financial-results-and-recent-business-highlights-302454283.html

    SOURCE INOVIO Pharmaceuticals, Inc.

    Get the next $INO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INO

    DatePrice TargetRatingAnalyst
    5/14/2024$20.00Overweight
    Stephens
    1/25/2024$4.00Perform → Outperform
    Oppenheimer
    11/9/2022Buy → Hold
    Maxim Group
    11/1/2022$2.00Neutral → Underperform
    BofA Securities
    7/19/2022$5.00 → $4.00Sector Perform
    RBC Capital Mkts
    5/11/2022Outperform → Perform
    Oppenheimer
    3/2/2022$6.00 → $5.00Sector Perform
    RBC Capital
    1/21/2022$8.00 → $10.00Underperform → Neutral
    B of A Securities
    More analyst ratings

    $INO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

      On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgeryAnnounced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encod

      5/13/25 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Present at Upcoming Scientific and Investor Conferences

      PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.

      4/30/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Inovio Pharma with a new price target

      Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

      5/14/24 8:01:14 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

      1/25/24 7:27:17 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma downgraded by Maxim Group

      Maxim Group downgraded Inovio Pharma from Buy to Hold

      11/9/22 9:19:58 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Shea Jacqueline Elizabeth

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      5/21/25 4:58:59 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Humeau Laurent

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      5/21/25 4:58:48 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Director Zoth Lota S. converted options into 2,167 shares, increasing direct ownership by 33% to 8,726 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      5/21/25 4:58:38 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Financials

    Live finance-specific insights

    See more
    • INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

      On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgeryAnnounced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encod

      5/13/25 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

      3/18/25 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

      SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/26/24 4:01:17 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      1/22/24 10:20:28 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      7/10/23 2:07:33 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Leadership Updates

    Live Leadership Updates

    See more
    • INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

      PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

      1/9/25 8:04:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

      Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

      7/2/24 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

      PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic

      6/27/22 8:00:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    SEC Filings

    See more
    • SEC Form 8-K filed by Inovio Pharmaceuticals Inc.

      8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

      5/22/25 5:15:02 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

      5/13/25 4:08:16 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Inovio Pharmaceuticals Inc.

      10-Q - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

      5/13/25 4:00:52 PM ET
      $INO
      Medical/Dental Instruments
      Health Care